Skip to main content
SpringerLink
Log in
Book cover

Endocrine Hypertension pp 151–179Cite as

Hypertension in Growth Hormone Excess and Deficiency

  • Chapter
  • First Online:

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Cardiovascular and cerebrovascular morbidity and mortality are increased in both acromegaly and adult growth hormone deficiency (GHD), and a significant portion of this elevated risk can be attributed to hypertension. Despite taking into account the effects of derangement of other pituitary hormones that often accompany these conditions and of treatments used for acromegaly or GHD, much appears attributable to the direct and indirect effects of abnormal levels of GH or IGF-I themselves. The hypothesized mechanisms for hypertension have been the subjects of much more study in acromegaly than in GHD; but at present there is no clear consensus on the most important abnormalities underlying hypertension in either condition, nor even on its prevalence, with a wide range of estimates from less than 20% to more than 70% in acromegaly, and 25–30% in GHD. The divergent results arise from differences in the techniques used to measure blood pressure and also the rates of hypertension in the background populations. Mechanisms postulated to underlie hypertension in acromegaly include expansion of plasma volume, direct renal effects, changes in vascular compliance, increased sympathetic tone, and indirect effects due to insulin resistance and to sleep apnea. Hypothesized mechanisms in GHD include endothelial dysfunction and increased vascular stiffness; but several other factors, such as increased sympathetic tone, paradoxically overlap with factors thought to play a role in acromegaly as well. This overlap may signify a U-shaped curve for the effects of GH and IGF-I on blood pressure regulation, with optimum effects within the normal range, but data are currently insufficient to demonstrate this with any certainty. Perhaps the strongest evidence linking acromegaly with abnormal BP is resolution or improvement of hypertension with successful treatment of GH excess.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Colao A, Di Somma C, Cascella T, et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol. 2008;159(4):389–97.

    Article  PubMed  CAS  Google Scholar 

  2. Hunt KJ, Lukanova A, Rinaldi S, et al. A potential inverse association between insulin-like growth factor I and hypertension in a cross-sectional study. Ann Epidemiol. 2006;16(7):563–71.

    Article  PubMed  Google Scholar 

  3. Landin-Wllhelmsen K, Wllhelmsen L, Lappast G, et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol. 1994;41(3):351–7.

    Article  Google Scholar 

  4. Capoluongo E, Pitocco D, Lulli P, et al. Inverse correlation between serum free IGF-I and IGFBP-3 levels and blood pressure in patients affected with type 1 diabetes. Cytokine. 2006;34(5–6):303–11.

    Article  PubMed  CAS  Google Scholar 

  5. Colangelo LA, Liu K, Gapstur SM. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and cardiovascular disease risk factors in young black men and white men: the CARDIA Male Hormone Study. Am J Epidemiol. 2004;160(8):750–7.

    Article  PubMed  Google Scholar 

  6. Andronico G, Mangano MT, Nardi E, et al. Insulin-like growth factor 1 and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy. J Hypertens. 1993;11(10):1097–101.

    Article  PubMed  CAS  Google Scholar 

  7. Díez J, Laviades C. Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril. J Hypertens Suppl. 1994;12(4):S31–6.

    PubMed  Google Scholar 

  8. Courville C, Mason VR. The heart in acromegaly. Arch Intern Med. 1938;61(5):704–13.

    Article  Google Scholar 

  9. Lie JT. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J. 1980;100(1):41–52.

    Article  PubMed  CAS  Google Scholar 

  10. Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2000;85(1):193–9.

    Article  PubMed  CAS  Google Scholar 

  11. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667–74.

    Article  PubMed  CAS  Google Scholar 

  12. Melmed S. Clinical perspective. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab. 2001;86(7):2929–34.

    Article  PubMed  CAS  Google Scholar 

  13. Colao A, Terzolo M, Bondanelli M, et al. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin Endocrinol. 2008;69(4):613–20.

    Article  Google Scholar 

  14. Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol. 2005;63(4):470–6.

    Article  Google Scholar 

  15. Ciresi A, Amato MC, Vetro C, et al. Adrenal morphology and function in acromegalic patients in relation to disease activity. Endocrine. 2009;36(2):346–54.

    Article  PubMed  CAS  Google Scholar 

  16. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.

    PubMed  Google Scholar 

  17. Minniti G, Moroni C, Jaffrain-Rea ML, et al. Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring. Clin Endocrinol. 1998;48(2):149–52.

    Article  CAS  Google Scholar 

  18. Jaffrain-Rea M, Moroni C, Baldelli R, et al. Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol. 2001;54(2):189–95.

    Article  CAS  Google Scholar 

  19. Pietrobelli DJ, Akopian M, Olivieri AO, et al. Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values. J Hum Hypertens. 2001;15(9):601–5.

    Article  PubMed  CAS  Google Scholar 

  20. Jaffrain-Rea M, Minniti G, Moroni C, et al. Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol. 2003;148(2):193–201.

    Article  PubMed  CAS  Google Scholar 

  21. Terzolo M, Matrella C, Boccuzzi A, et al. Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. J Endocrinol Invest. 1999;22(1):48–54.

    PubMed  CAS  Google Scholar 

  22. Obara T, Ohkubo T, Imai Y. Long-term risk in subjects with white-coat hypertension. Hypertension. 2009;54(5):e133.

    Article  PubMed  CAS  Google Scholar 

  23. Kraatz C, Benker G, Weber F, et al. Acromegaly and hypertension: Prevalence and relationship to the renin-angiotensin-aldosterone system. J Mol Med. 1990;68(12):583–7.

    CAS  Google Scholar 

  24. Rodrigues EA, Caruana MP, Lahiri A, et al. Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle. Br Heart J. 1989;62(3):185–94.

    Article  PubMed  CAS  Google Scholar 

  25. Ohtsuka H, Komiya I, Aizawa T, Yamada T. Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-I production. Endocr J. 1995;42(6):781–7.

    Article  PubMed  CAS  Google Scholar 

  26. Colao A, Pivonello R, Spinelli L, et al. A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients. J Endocrinol Invest. 2007;30(6):497–506.

    PubMed  CAS  Google Scholar 

  27. Sucunza N, Barahona MJ, Resmini E, et al. Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. Eur J Endocrinol. 2008;159(6):773–9.

    Article  PubMed  CAS  Google Scholar 

  28. Fallo F, Barzon L, Boscaro M, Casiglia E, Sonino N. Effect of octreotide on 24-h blood pressure profile in acromegaly. Am J Hypertens. 1998;11(5):591–6.

    Article  PubMed  CAS  Google Scholar 

  29. Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: A prospective study. J Clin Endocrinol Metab. 2009;94(10):3746–56.

    Article  PubMed  CAS  Google Scholar 

  30. Delaroudis SP, Efstathiadou ZA, Koukoulis GN, et al. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol. 2008;69(2):279–84.

    Article  CAS  Google Scholar 

  31. Melnichenko G, Syirkin A, Pronin V, et al. Prevalence and peculiarity of arterial hypertension treatment in acromegaly patients; 2009. Available at: http://www.endocrine-abstracts.org/ea/0020/ea0020P293.htm. Accessed 21 Jan 2010.

  32. Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol. 2003;58(2):169–76.

    Article  CAS  Google Scholar 

  33. Biermasz NR, Pereira AM, Smit JWA, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab. 2005;90(5):2731–9.

    Article  PubMed  CAS  Google Scholar 

  34. Colao A, Pivonello R, Galderisi M, et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab. 2008;93(7):2639–46.

    Article  PubMed  CAS  Google Scholar 

  35. Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 2006;154(3):467–77.

    Article  PubMed  CAS  Google Scholar 

  36. Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab. 2004;89(2):658–61.

    Article  PubMed  CAS  Google Scholar 

  37. Maison P, Tropeano A, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: A metaanalysis. J Clin Endocrinol Metab. 2007;92(5):1743–7.

    Article  PubMed  CAS  Google Scholar 

  38. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85(2):526–9.

    Article  PubMed  CAS  Google Scholar 

  39. Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly. J Clin Endocrinol Metab. 2000;85(9):3132–40.

    Article  PubMed  CAS  Google Scholar 

  40. Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab. 2005;90(4):1972–8.

    Article  PubMed  CAS  Google Scholar 

  41. Damjanovic SS, et al. Clinical indicators of biochemical ­remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clin Endocrinol (Oxf). 2005;62(4):410–7.

    Article  CAS  Google Scholar 

  42. Cuspidi C, Macca G, Sampieri L, et al. Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J Hypertens. 2001;19(9):1539–45.

    Article  PubMed  CAS  Google Scholar 

  43. Bjorklund K, Lind L, Andren B, Lithell H. The majority of nondipping men do not have increased cardiovascular risk: a population-based study. J Hypertens. 2002;20(8):1501–6.

    Article  PubMed  CAS  Google Scholar 

  44. Vasunta RL, Kesaniemi YA, Ukkola O. Plasma adiponectin concentration is associated with ambulatory daytime systolic blood pressure but not with the dipping status. J Hum Hypertens. 2009. Available at: http://dx.doi.org/10.1038/jhh.2009.98. Accessed 8 Feb 2010.

    Google Scholar 

  45. Paisley A, Roberts M, Heagerty A, Trainer P. 24-hour ambulatory blood pressure monitoring (ABPM) in patients with acromegaly and the value of clinic blood pressure measurements. Available at: http://www.endocrine-abstracts.org/ea/0007/ea0007P127.htm. Accessed 5 Feb 2010.

  46. Gibney J, Wolthers T, Burt MG, et al. Protein metabolism in acromegaly: differential effects of short- and long-term treatment. J Clin Endocrinol Metab. 2007;92(4):1479–84.

    Article  PubMed  CAS  Google Scholar 

  47. Bengtsson B-Å, Brummer RM, Eden S, Bosaeus I. Body composition in acromegaly. Clin Endocrinol. 1989;30(2):121–30.

    Article  CAS  Google Scholar 

  48. Møller J. Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm IGF Res. 2003;13(2–3):55–74.

    Article  PubMed  CAS  Google Scholar 

  49. Katznelson L. Alterations in body composition in acromegaly. Pituitary. 2009;12(2):136–42.

    Article  PubMed  CAS  Google Scholar 

  50. Ikkos D, Luft R, Sjögren B. Body water and sodium in patients with acromegaly. J Clin Invest. 1954;33(7):989–94.

    Article  PubMed  CAS  Google Scholar 

  51. Hammerman MR, Miller SB. Renal cellular biology of growth hormone and insulin-like growth factor I. Pediatr Nephrol. 1991;5(4):505–8.

    Article  PubMed  CAS  Google Scholar 

  52. Biglieri EG, Watlington CO, Forsham PH. Sodium retention with human growth hormone and its subfractions. J Clin Endocrinol Metab. 1961;21(4):361–70.

    Article  CAS  Google Scholar 

  53. Ng LL, Evans DJ. Leucocyte sodium transport in acromegaly. Clin Endocrinol (Oxf). 1987;26(4):471–80.

    Article  CAS  Google Scholar 

  54. Salomon F, Cuneo RC, Hesp R, et al. Basal metabolic rate in adults with growth hormone deficiency and in patients with acromegaly: relationship with lean body mass, plasma insulin level and leucocyte sodium pump activity. Clin Sci. 1992;83(3):325–30.

    PubMed  CAS  Google Scholar 

  55. Christiansen JS, Gammelgaard J, Ørskov H, et al. Kidney function and size in normal subjects before and during growth hormone administration for one week. Eur J Clin Invest. 1981;11(6):487–90.

    Article  PubMed  CAS  Google Scholar 

  56. Falkheden T, Sjogren B. Extracellular fluid volume and renal function in pituitary insufficiency and acromegaly. Acta Endocrinol. 1964;46(1):80–8.

    PubMed  CAS  Google Scholar 

  57. Guler HP, Schmid C, Zapf J, Froesch ER. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA. 1989;86(8):2868–72.

    Article  PubMed  CAS  Google Scholar 

  58. Deray G, Chanson P, Maistre G, et al. Atrial natriuretic factor in patients with acromegaly. Eur J Clin Pharmacol. 1990;38(5):409–13.

    Article  PubMed  CAS  Google Scholar 

  59. Hall C, Rouleau JL, Moyè L, et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994;89(5):1934–42.

    Article  PubMed  CAS  Google Scholar 

  60. McKnight JA, McCance DR, Hadden DR, et al. Basal and saline-stimulated levels of plasma atrial natriuretic factor in acromegaly. Clin Endocrinol (Oxf). 1989;31(4):431–8.

    Article  CAS  Google Scholar 

  61. Cain JP, Williams GH, Dluhy RG. Plasma renin activity and aldosterone secretion in patients with acromegaly. J Clin Endocrinol Metab. 1972;34(1):73–81.

    Article  PubMed  CAS  Google Scholar 

  62. Mulatero P, Veglio F, Maffei P, et al. CYP11B2–344T/C Gene polymorphism and blood pressure in patients with acromegaly. J Clin Endocrinol Metab. 2006;91(12):5008–12.

    Article  PubMed  CAS  Google Scholar 

  63. Moller J, Moller N, Frandsen E, et al. Blockade of the renin-angiotensin-aldosterone system prevents growth hormone-induced fluid retention in humans. Am J Physiol Endocrinol Metab. 1997;272(5):E803–8.

    CAS  Google Scholar 

  64. Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore). 1994;73(5):233–40.

    CAS  Google Scholar 

  65. Ikeda T, Terasawa H, Ishimura M, et al. Correlation between blood pressure and plasma insulin in acromegaly. J Intern Med. 1993;234(1):61–3.

    Article  PubMed  CAS  Google Scholar 

  66. Słowińska-Srzednicka J, Zgliczyński S, Soszyński P, Zgliczyński W, Jeske W. High blood pressure and hyperinsulinaemia in acromegaly and in obesity. Clin Exp Hypertens A. 1989;11(3):407–25.

    Article  PubMed  Google Scholar 

  67. DeFronzo RA. The effect of insulin on renal sodium metabolism. Diabetologia. 1981;21(3):165–71.

    Article  PubMed  CAS  Google Scholar 

  68. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334(6):374–82.

    Article  PubMed  CAS  Google Scholar 

  69. Rozenberg I, Manchon P, Sabetier C, Hazard J, Lhoste F. Effects of thyrotrophin-releasing hormone on plasma catecholamine levels in acromegalics. Acta Endocrinol. 1985;109(1):19–24.

    PubMed  CAS  Google Scholar 

  70. Rio G, Velardo A, Mascadri C, et al. Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: acute effects of continuous octreotide infusion. Eur J Endocrinol. 2000;142(2):179–86.

    Article  PubMed  CAS  Google Scholar 

  71. Cryer PE. Plasma norepinephrine and epinephrine in acromegaly. J Clin Endocrinol Metab. 1975;41(3):542–5.

    Article  PubMed  CAS  Google Scholar 

  72. Loon GRV. Abnormal plasma catecholamine responses in acromegalics. J Clin Endocrinol Metab. 1979;48(5):784–9.

    Article  PubMed  Google Scholar 

  73. Moore TJ, Thein-Wai W, Dluhy RG, et al. Abnormal adrenal and vascular responses to angiotensin II and an angiotensin antagonist in acromegaly. J Clin Endocrinol Metab. 1980;51(2):215–22.

    Article  PubMed  CAS  Google Scholar 

  74. Capaldo B, Lembo G, Rendina V, et al. Muscle sympathetic nerve activity in patients with acromegaly. J Clin Endocrinol Metab. 2000;85(9):3203–7.

    Article  PubMed  CAS  Google Scholar 

  75. Bondanelli M, Ambrosio MR, Franceschetti P, et al. Diurnal rhythm of plasma catecholamines in acromegaly. J Clin Endocrinol Metab. 1999;84(7):2458–67.

    Article  PubMed  CAS  Google Scholar 

  76. Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 2001;4(4):239–49.

    Article  PubMed  CAS  Google Scholar 

  77. Clayton RN. Cardiovascular function in acromegaly. Endocr Rev. 2003;24(3):272–7.

    Article  PubMed  CAS  Google Scholar 

  78. Thuesen L, Christensen SE, Weeke J, Orskov H, Henningsen P. A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients? Acta Med Scand. 1988;223(4):337–43.

    Article  PubMed  CAS  Google Scholar 

  79. Chanson P, Megnien JL, del Pino M, et al. Decreased regional blood flow in patients with acromegaly. Clin Endocrinol (Oxf). 1998;49(6):725–31.

    Article  CAS  Google Scholar 

  80. Maison P, Demolis P, Young J, et al. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol. 2000;53(4):445–51.

    Article  CAS  Google Scholar 

  81. Colao A, Spiezia S, Cerbone G, et al. Increased arterial intima-media thickness by B-M mode echo Doppler ultrasonography in acromegaly. Clin Endocrinol (Oxf). 2001;54(4):515–24.

    Article  CAS  Google Scholar 

  82. Brevetti G, Marzullo P, Silvestro A, et al. Early vascular alterations in acromegaly. J Clin Endocrinol Metab. 2002;87(7):3174–9.

    Article  PubMed  CAS  Google Scholar 

  83. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62(2):347–504.

    PubMed  CAS  Google Scholar 

  84. Colao A, Marzullo P, Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol. 2002;146(3):303–9.

    Article  PubMed  CAS  Google Scholar 

  85. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–52.

    Article  PubMed  CAS  Google Scholar 

  86. Fatti LM, Scacchi M, Pincelli AI, Lavezzi E, Cavagnini F. Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary. 2001;4(4):259–62.

    Article  PubMed  CAS  Google Scholar 

  87. van Haute FRB, Taboada GF, Correa LL, et al. Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging. Eur J Endocrinol. 2008;158(4):459–65.

    Article  PubMed  CAS  Google Scholar 

  88. Ronconi V, Giacchetti G, Mariniello B, et al. Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Press. 2005;14(4):227–32.

    Article  PubMed  CAS  Google Scholar 

  89. Lanfranco F, Motta G, Minetto MA, Baldi M, Balbo M, Ghigo E, Arvat E, Maccario M. Neuroendocrine alterations in obese patients with sleep apnea syndrome. Int J Endocrinol. 2010;article 474518:11.

    Google Scholar 

  90. Maison P, Griffin S, Nicoue-Beglah M, et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2004;89(5):2192–9.

    Article  PubMed  CAS  Google Scholar 

  91. Cittadini A, Cuocolo A, Merola B, et al. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol. 1994;267(2 Pt 1):E219–25.

    PubMed  CAS  Google Scholar 

  92. McCallum RW, Petrie JR, Dominiczak AF, Connell JMC. Growth hormone deficiency and vascular risk. Clin Endocrinol. 2002;57(1):11–24.

    Article  CAS  Google Scholar 

  93. Svensson J, Bengtsson B-Å, Rosen T, Oden A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab. 2004;89(7):3306–12.

    Article  PubMed  CAS  Google Scholar 

  94. Ahmad AM, Hopkins MT, Weston PJ, Fraser WD, Vora JP. Effects of GH replacement on 24-h ambulatory blood pressure and its circadian rhythm in adult GH deficiency. Clin Endocrinol. 2002;56(4):431–7.

    Article  CAS  Google Scholar 

  95. Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson B. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol. 1993;129(3):195–200.

    PubMed  CAS  Google Scholar 

  96. Sanmarti A, Lucas A, Hawkins F, Webb S, Ulied A. Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study). Socio-economic impact and health status. Collaborative ODA (observational GH deficiency in adults) group. Eur J Endocrinol. 1999;141(5):481–9.

    Article  PubMed  CAS  Google Scholar 

  97. Barreto-Filho JAS, Alcantara MRS, Salvatori R, et al. Familial isolated growth hormone deficiency is associated with increased systolic blood pressure, central obesity, and dyslipidemia. J Clin Endocrinol Metab. 2002;87(5):2018–23.

    Article  PubMed  CAS  Google Scholar 

  98. Maheshwari HG, Silverman BL, Dupuis J, Baumann G. Phenotype and genetic analysis of a syndrome caused by an inactivating mutation in the growth hormone-releasing hormone receptor: Dwarfism of Sindh. J Clin Endocrinol Metab. 1998;83(11):4065–74.

    Article  PubMed  CAS  Google Scholar 

  99. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958–2003. J Clin Endocrinol Metab. 2004;89(3):1031–44.

    Article  PubMed  CAS  Google Scholar 

  100. Caidahl K, Edén S, Bengtsson BA. Cardiovascular and renal effects of growth hormone. Clin Endocrinol (Oxf). 1994;40(3):393–400.

    Article  CAS  Google Scholar 

  101. Fideleff HL, Boquete HR, Stalldecker G, Giaccio AV, Sobrado PGV. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients. Growth Horm IGF Res. 2008;18(4):318–24.

    Article  PubMed  CAS  Google Scholar 

  102. Chrisoulidou A, Beshyah SA, Rutherford O, et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab. 2000;85(10):3762–9.

    Article  PubMed  CAS  Google Scholar 

  103. Abs R, Feldt-Rasmussen U, Mattsson AF, et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults–a KIMS database analysis. Eur J Endocrinol. 2006;155(1):79–90.

    Article  PubMed  CAS  Google Scholar 

  104. Monson JP, Abs R, Bengtsson B-Å, et al. Growth hormone deficiency and replacement in elderly hypopituitary adults. KIMS Study Group and the KIMS International Board, Pharmacia and Upjohn International Metabolic Database. Clin Endocrinol (Oxf). 2000;53(3):281–9.

    Article  CAS  Google Scholar 

  105. Salerno M, Esposito V, Farina V, et al. Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case–control study. J Clin Endocrinol Metab. 2006;91(4):1288–95.

    Article  PubMed  CAS  Google Scholar 

  106. Kokshoorn N, Biermasz NR, Roelfsema F, et al. Growth hormone replacement therapy in elderly growth hormone deficient patients: a systematic review. Eur J Endocrinol. 2011;164(5):657–65.

    Google Scholar 

  107. Abdu TAM, Elhadd TA, Buch H, et al. Recombinant GH replacement in hypopituitary adults improves endothelial cell function and reduces calculated absolute and relative coronary risk. Clin Endocrinol. 2004;61(3):387–93.

    Article  CAS  Google Scholar 

  108. Smith JC, Evans LM, Wilkinson I, et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol. 2002;56(4):493–501.

    Article  CAS  Google Scholar 

  109. Krzyzanowska K, Schnack C, Mittermayer F, et al. High prevalence of abnormal circadian blood pressure regulation and impaired glucose tolerance in adults with hypopituitarism. Exp Clin Endocrinol Diabetes. 2005;113(8):430–4.

    Article  PubMed  CAS  Google Scholar 

  110. Moller J, Fisker S, Rosenfalck A, et al. Long-term effects of growth hormone (GH) on body fluid distribution in GH deficient adults: a four months double blind placebo controlled trial. Eur J Endocrinol. 1999;140(1):11–6.

    Article  PubMed  CAS  Google Scholar 

  111. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994;15(5):555–73.

    PubMed  Google Scholar 

  112. Hoffman D, Crampton L, Sernia C, Nguyen T, Ho K. Short-term growth hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. J Clin Endocrinol Metab. 1996;81(3):1123–8.

    Article  PubMed  CAS  Google Scholar 

  113. Møller J, Jørgensen JO, Møller N, et al. Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man. J Clin Endocrinol Metab. 1991;72(4):768–72.

    Article  PubMed  Google Scholar 

  114. Salomon F, Cuneo RC, Hesp R, Sönksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989;321(26):1797–803.

    Article  PubMed  CAS  Google Scholar 

  115. Attanasio AF, Mo D, Erfurth EM, et al. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab. 2010;95(1):74–81.

    Article  PubMed  CAS  Google Scholar 

  116. Böger RH. Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans. J Endocrinol Invest. 1999;22(5 Suppl):75–81.

    PubMed  Google Scholar 

  117. Böger RH, Skamira C, Bode-Böger SM, et al. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest. 1996;98(12):2706–13.

    Article  PubMed  Google Scholar 

  118. Capaldo B, Guardasole V, Pardo F, et al. Abnormal vascular reactivity in growth hormone deficiency. Circulation. 2001;103(4):520–4.

    Article  PubMed  CAS  Google Scholar 

  119. Franklin SS. Arterial stiffness and hypertension: a two-way street? Hypertension. 2005;45(3):349–51.

    Article  PubMed  CAS  Google Scholar 

  120. Cuneo RC, Salomon F, Wilmshurst P, et al. Cardiovascular effects of growth hormone treatment in growth-hormone-deficient adults: stimulation of the renin-aldosterone system. Clin Sci. 1991;81(5):587–92.

    PubMed  CAS  Google Scholar 

  121. Sverrisdottir YB, Elam M, Herlitz H, Bengtsson B-Å, Johannsson G. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab. 1998;83(6):1881–5.

    Article  PubMed  CAS  Google Scholar 

  122. Egecioglu E, Andersson IJ, Bollano E, et al. Growth hormone receptor deficiency in mice results in reduced systolic blood pressure and plasma renin, increased aortic eNOS expression, and altered cardiovascular structure and function. Am J Physiol Endocrinol Metab. 2007;292(5):E1418–25.

    Article  PubMed  CAS  Google Scholar 

  123. Nabarro JDN. Acromegaly. Clin Endocrinol (Oxf). 1987;26:481–512.

    Google Scholar 

  124. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clinics N Am. 1992;21:597–614.

    Google Scholar 

  125. Lopez-Velasco R, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab. 1997;82:1047–53.

    Google Scholar 

  126. Fukuda I, Hizuka N, Murakami Y, Itoh E, Yasumoto K, Sata A, et al. Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women’s Medical University. Internal Medicine. 2001;40:987–92.

    Google Scholar 

  127. Otsuki M, et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf). 54:791–96.

    Google Scholar 

  128. Weiss V, et al. Prevalence of the sleep apnea syndrome in acromegaly population. J Endocrinol Invest. 2001;23:515–19.

    Google Scholar 

  129. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151(4):439–46.

    Google Scholar 

Download references

Acknowledgment

We gratefully acknowledge the assistance of Ms. Monica Kletke in the ­preparation of this chapter.

Author information

Authors and Affiliations

  1. Bristol Royal Infirmary, University of Bristol Faculty of Medicine, Bristol, UK

    Daniel H. P. Towie

  2. Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington School of Medicine, VA Puget Sound Health Care System, 9600 Veterans Drive SW, Tacoma, WA, 98493, USA

    George R. Merriam

Authors
  1. Daniel H. P. Towie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George R. Merriam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George R. Merriam .

Editor information

Editors and Affiliations

  1. Dept. Medicine, Div. Endocrinology, Diabetes &, University of Mississippi Medical Center, N. State Street 2500, Jackson, 39216, Mississippi, USA

    Christian A Koch

  2. UNESCO Chair on Adolescent Health Care, Division of Endocrinology, University of Athens Medical School, Aghia Sophia Children's Hospital, Athens, 11527, Greece

    George P Chrousos

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Towie, D.H.P., Merriam, G.R. (2013). Hypertension in Growth Hormone Excess and Deficiency. In: Koch, C., Chrousos, G. (eds) Endocrine Hypertension. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-548-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-548-4_8

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-547-7

  • Online ISBN: 978-1-60761-548-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation